AGTC Announces Financial Results and Business Update for the Quarter Ended March 31, 2019

UF startup Applied Genetic Technologies Corporation, a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, announced financial results for the quarter ended March 31, 2019. AGTC is a graduate of UF Innovate | Sid Martin Biotech.

“Completing enrollment in the dose escalation portion of our Phase 1/2 trial in patients with achromatopsia due to mutations in the CNGB3 gene and the expansion cohort of our Phase 1/2 trial in patients with X-linked retinitis pigmentosa demonstrates our clinical development progress and keeps us on track to report multiple data sets in the second half of 2019,” said Sue Washer, President and CEO of AGTC. “Achieving these clinical milestones reflects our continued progress and commitment to developing new approaches to treat inherited retinal diseases positioning AGTC well to create value for patients and shareholders.”

Learn more about AGTC Announces Financial Results and Business Update for the Quarter Ended March 31, 2019.